4.810USD+7.61%Mkt Cap: 63.26M USDP/E: —Last update: 2026-05-26
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United Sta…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap63.26M USD
Enterprise Value44.46M USD
Revenue (TTM)—
Gross Profit-9.77M USD
Net Income (TTM)-22.45M USD
Revenue/Share—
Last Price4.810 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.48
PEG—
EV/EBITDA-1.88
EV/Revenue—
P/S—
P/B2.99
EPS (TTM)-4.33
EPS (Forward)-1.92
52W Range
3.20019% of range11.89
52W High11.89 USD
52W Low3.200 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-894.81%
ROA-148.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.25M USD
CapEx (TTM)162.14K USD
FCF Margin—
FCF Yield-19.21%
Net Debt-18.46M USD
Net Debt/EBITDA0.78
Balance Sheet
Debt/Equity3.50
Current Ratio2.55
Quick Ratio2.37
Book Value/Sh1.584 USD
Cash/Share1.950 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateAug 9, 2024
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)25.90 USD
Target Range8.000 USD – 55.00 USD
# Analysts5
Ownership
Shares Out.13.28M
Float12.91M
Insiders30.97%
Institutions8.99%
Short Interest
Short Ratio3.3d
Short % Float14.90%
Short % Out.12.21%
Shares Short1.50M
Short (prev mo.)1.08M
Technical
SMA 505.963 (-19.3%)
SMA 2004.901 (-1.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)472.06K
Avg Vol (10d)429.50K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—